Angiotensinogen polymorphism is associated with risk for malignancy but not for oral cancer.
Vairaktaris E, Yapijakis C, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Critselis E, Avgoustidis D, Neukam F, Patsouris E.
Vairaktaris E, et al. Among authors: avgoustidis d.
Anticancer Res. 2008 May-Jun;28(3A):1675-9.
Anticancer Res. 2008.
PMID: 18630525
Free article.